Summary

On September 7, 2026, Minoryx Therapeutics reported the successful completion of recruiting a Clinical Phase 3 Global Lead for CALYX (NEZGLYAL), an investigational therapy for adults with cerebral adrenoleucoma CALD. This rare neurological disorder offers no approved drugs, making the study pivotal for patients unable to access medical treatment options. Simultaneously, On September 7, 2026, the seed round funding of $15 million was launched by Asabys Partners. This new venture, led by a member of Catalonia.health expertise in life science and quality, aims to accelerate the diagnosis and prevention complications associated with Lemeras disease through innovative molecular diagnostics technologies.

The collaborative effort between Minoryx Therapeutics, an established member of Catalonia.health, and Asabys Partners represents a significant step forward in advancing neurological disease research under stringent regulatory constraints.

Title

Catalonia.health Science. Innovation. Business | Inici

Description

Catalonia.health aglutina l'ecosistema de la salut a Catalunya. Connectem empreses, startups i recerca per impulsar la innovació i el creixement internacional.

Categories

Health

Downstreams

twitter.com, flickr.com, youtube.com, linkedin.com

NS Lookup

A 52.50.27.241

Dates

Created 2024-10-13

Updated 2026-10-22

Summarized 2026-10-22